C. Faria

发表

Comparative Effectiveness and Resource Usage in Patients Receiving First‐line Taxane‐based Chemotherapy for Stage IV Non–Small‐cell Lung Cancer in a US Community Oncology Setting

Manish B. Patel, J. Weiss, Sandra Margunato‐Debay, 2017, Clinical lung cancer.

Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.

H. Rugo, G. Dranitsaris, S. Gluck, 2015, Clinical therapeutics.

Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer.

R. Copher, C. Faria, Marco daCosta DiBonaventura, 2014, American health & drug benefits.

Treatment of Peripheral T‐Cell Lymphoma in Community Settings

A. Goy, S. Goldberg, T. Feldman, 2017, Clinical lymphoma, myeloma & leukemia.

Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis.

Xuan Li, A. McBride, N. Nagl, 2014, American health & drug benefits.

A narrative review of clinical inertia: focus on hypertension.

D. Belletti, Karen W. Lee, C. Faria, 2009, Journal of the American Society of Hypertension : JASH.

Comparative Effectiveness of Dalteparin and Enoxaparin in a Hospital Setting

A. Powers, Y. Choe, C. Faria, 2012, Journal of pharmacy practice.

The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature.

M. Broder, D. Cherepanov, A. Powers, 2014, American health & drug benefits.

A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome

K. Johnston, E. Popoff, K. Myren, 2020, Journal of medical economics.

Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care.

M. Broder, D. Cherepanov, A. Powers, 2012, American health & drug benefits.

Indirect costs associated with metastatic breast cancer

L. Schwartzberg, Xin Gao, Y. Wan, 2013, Journal of medical economics.

P1-08-07: Survival in US Women Following an Indication of Metastatic Breast Cancer Diagnosis and Chemotherapy Initiation: A SEER-Medicare Analysis.

H. Rugo, K. Clements, Douglas C. A. Taylor, 2011 .

Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Manish B. Patel, F. Braiteh, C. Faria, 2017, Cancer management and research.

Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis

F. Braiteh, S. Glück, R. Mahtani, 2018, Cancer management and research.

Economic Burden of Chemotherapy Related Toxicities in Third Line Metastatic Breast Cancer Patients.

A. Forsythe, G. Tremblay, S. McCutcheon, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting

G. Dranitsaris, S. Blau, C. Faria, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Original article Indirect costs associated with metastatic breast cancer

L. Schwartzberg, Xin Gao, Y. Wan, 2013 .

Probable Warfarin Interaction with Menthol Cough Drops

C. Faria, K. Coderre, Earl Dyer, 2010, Pharmacotherapy.

A narrative review of clinical inertia: focus on hypertension.

D. Belletti, Karen W. Lee, C. Faria, 2009, Journal of the American Society of Hypertension : JASH.